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Introduction
Since the discovery of the first causative mutations for cardiomyopathies in the early 1990s, the importance of inherited genetic variants has been increasingly recognized. 1, 2 These discoveries have led to a better understanding of disease pathogenesis and introduced genetic evaluation into clinical practice for affected individuals and their relatives. 2, 3 Early identification of asymptomatic mutation carriers via genetic cascade screening is potentially of major prognostic importance, as cardiomyopathies can lead to sudden cardiac death (SCD) as a result of malignant ventricular arrhythmias even before the onset of any symptoms. 2 Although our knowledge of the genetics of cardiomyopathies has expanded greatly, mutation carriers are mostly advised, among other as to lifestyle adjustments (i.e. sports activity), and treated based on general guidelines based on their cardiac morphological and functional characteristics; there is little known about specific genotype-phenotype relationships. 2, 4 Phospholamban (encoded by the PLN gene) is a transmembrane sarcoplasmic reticulum (SR) phosphoprotein and is a key regulator of calcium homeostasis. 5 Pathogenic mutations in PLN, mostly leading to inhibition of the calcium uptake into the SR, may cause inherited cardiomyopathy. 5 The pathogenic PLN R14del mutation is identified in patients diagnosed with arrhythmogenic cardiomyopathy, in which initially a diagnosis of dilated cardiomyopathy (DCM) or arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) has been made. [6] [7] [8] [9] In the Netherlands, the PLN R14del mutation is a founder mutation and has been identified in 10-15% of patients diagnosed with either DCM or ARVC/D. [9] [10] [11] [12] The phenotype of PLN R14del carriers, derived from a limited number of index patients and their families, is characterized by a low voltage electrocardiogram (ECG), a high frequency of malignant ventricular arrhythmias and end-stage heart failure. [6] [7] [8] [9] 12 In order to obtain insight into the natural ore the onset of an n n ny y y y tics; th th th ther er er ere e e i is l l lit it ittl l tl tle e kn kn k ow own ab ab ab bo o o out sp p pec ec ecif if if ifi i ic ge ge geno noty y yp p pe pe-p p -ph h h heno no no ot t ty type pe r relat at at atio io io i nshi hi hips ps. history of this inherited disorder, including disease onset and mortality, a large and unselected multicentre cohort consisting of both index patients and relatives must be studied. 13 Moreover, risk stratification for malignant ventricular arrhythmias is essential in preventing SCD.
In the present study, we therefore evaluated the mortality, cardiac disease outcome and possible risk factors for malignant ventricular arrhythmias in the largest cohort of individuals carrying a single cardiomyopathy-related mutation, PLN R14del.
Methods

Study population and clinical data
Data were collected from index patients and relatives in whom the pathogenic PLN R14del and/or a family history suggestive of an inherited cardiomyopathy. 9 Index patients in the cohort were not known to be related to each other. Clinical data were collected retrospectively from all PLN R14del mutation carriers > 16 years old, who were evaluated by a cardiologist. We collected all available baseline clinical information from the first documented cardiac evaluation and follow-ups. Since the data was collected retrospectively no standardized diagnostic and therapeutic protocols were used. Clinical evaluations were performed as standard clinical care.
Individuals were divided into two subgroups: a symptomatic group in which the first referral to the cardiologist was instigated by cardiac symptoms, and an asymptomatic group whose referral was because of a positive family history for SCD, cardiomyopathy and/or collected from index patients and relatives in whom the pathogenic PLN R14del 
Clinical definitions
DCM was diagnosed if an individual had both a reduced left ventricular ejection fraction (LVEF) < 45% and dilation of the LV on echocardiography (LV end-diastolic dimension > 112% of the predicted value corrected for body surface area and age). 14, 15 ARVC/D was diagnosed based on the modified task force criteria (TFC). 16 Right ventricular (RV) dysfunction was defined as RVEF < 45% and/or tricuspid annular plane systolic excursion (TAPSE) < 14 mm. 16 The occurrence of ventricular arrhythmias and ECG abnormalities were specifically documented. Ventricular arrhythmias were classified as non-sustained VT (3 or more consecutive ventricular complexes with a rate of > 100 per min and a duration of < 30 seconds), sustained VT (ventricular complexes with a rate of > 100 per min with a duration of >30 seconds) and > 500 ventricular premature complexes (VPC) per 24 hours on Holter monitoring.
Atrial tachyarrhythmias were classified as paroxysmal, persistent, permanent atrial fibrillation, and atrial flutter.
ECG abnormalities were classified as atrioventricular (AV)-conduction abnormalities (defined as a first degree AV-conduction abnormality when the PR-interval was > 0.20 seconds, second-or third degree AV-conduction abnormalities), repolarization abnormalities (fulfilling the major or minor criteria as described in the modified ARVC/D TFC 16 ) and low voltage ECG (defined as QRS peak-to-peak amplitude in leads I, II, and III less than 0.5 mV, the sum of the amplitudes less than 1.5 mV and/or amplitude in all precordial leads less than 1.0 mV).
17, 18
The blood pressure (BP) response during symptom-limited exercise testing was considered abnormal when the systolic BP increases by less than 25 mmHg from baseline. Sports activity (from 16 years old until first cardiological evaluation) and physical activity half an hour before malignant ventricular arrhythmias were evaluated by questionnaires to assess the type, intensity and years of sport activity. These questionnaires were sent to mutation carriers who had genetic counselling at two of the university hospitals (Amsterdam and Groningen). Sport activities were classified according to current guidelines as < 10 years or > 10 years high dynamic sport activity (weekly and at least half an hour per week).
20
Cardiac disease outcome End-stage heart failure was defined as cardiac transplantation or death caused by heart failure.
Family tree mortality ratio method
The all-cause mortality was calculated using the family tree mortality ratio method. 21, 22 In order to observe the natural history of the disease, the observed mortality of mutation carriers was compared to that of the general Dutch population (expected), standardized for age, gender, and calendar period as described previously. 21 The ratio of observed to expected number of deaths is the standardized mortality ratio (SMR). We incorporated data from all mutation carriers from the age of 15 years until death due to all causes or until 2010 (when the PLN R14del mutation was 21 of these died prematurely) were included in calculation. The SMR was also calculated using a combined end-point for first occurrence of malignant ventricular arrhythmias, end-stage heart failure, and death due to all causes. The 95% CI of the SMR was calculated assuming a Poisson distribution for the observed number of deaths and by using exact limits.
Statistical analysis
Statistical calculations were performed using PASW 18.0 software (SPSS Inc., Chicago, Illinois, USA) and the R statistical package (version 2.10.1). 23 Categorical and continuous variables were compared using Pearson's Chi-squared test and Student's unpaired t test, respectively.
Categorical variables were corrected for family clustering by using generalized linear mixedeffects models.
Possible risk factors for malignant ventricular arrhythmias were first analyzed univariably using time-to-event analyses. The date of first cardiac evaluation was used as the starting point and the event was defined as the first occurrence of a malignant ventricular arrhythmia. In individuals without an event, the follow-up period extended to the most recent evaluation. The P values of time-to-event analyses were calculated using the log-rank test. All statistically significant variables in the univariable analysis were then included in a multivariable model. The multivariable analysis (Cox regression) was corrected for age of first visit to the cardiologist and family clustering. 24, 25 Independent risk factors were selected after backward stepwise regression.
We also calculated hazard ratios and 95% confidence intervals (CI). In all analyses a P value of < 0.05 was considered statistically significant. 
Results
Baseline characteristics
Of the 403 PLN R14del mutation carriers, cardiological data were available from 295 individuals ( Figure 1 ). These patients belong to 83 families, with 1-14 carriers per family. The symptomatic and asymptomatic group comprised 125 (42%) and 170 (58%) of the 295 individuals respectively ( Table 1 ). In one-fifth of the symptomatic individuals, the first presentation was sustained VT (16%) or successful cardiopulmonary resuscitation (4%). Sixteen (13%) symptomatic individuals had a history of unexplained syncope. Severe clinical symptoms of heart failure (New York Heart Association functional class, NYHA > 3) were present at baseline in 16% of the symptomatic individuals.
Symptomatic individuals were older than asymptomatic individuals (48±14 years vs. 
Mortality
The overall mortality was calculated for our cohort of 403 PLN R14del mutation carriers 
Cardiac disease outcome
The median follow-up period from first contact with the cardiologist was 42 months Figure 2) ; of whom 17 (52%) underwent a heart transplantation and 16
(48%) died due to heart failure. The youngest person in whom such an event occurred was 31 years old ( Figure 3) . The first malignant ventricular arrhythmia events occurred at a significantly younger age than the end-stage heart failure events (P = 0.04) (Figure 3 ).
Circumstances during malignant ventricular arrhythmias
Completed questionnaires were available for 185 of 212 individuals (87% response). The first event was a malignant ventricular arrhythmia in 24 (13%) of them: 18 received an appropriate ICD shock and 6 were resuscitated. In the majority (74%) of cases, the event occurred during exercise (2/3 during low intensity exercise and 1/3 during moderate-high intensity exercise). The circumstances surrounding SCD were known for 19 individuals, 13 (68%) of whom died during exercise.
Risk factors for malignant ventricular arrhythmias
Possible risk factors for malignant ventricular arrhythmias were analyzed in a univariable model (Table 3) . LVEF < 45% and sustained or non-sustained VT were highly significant risk factors Table 3) . After Bonferroni adjustment for multiple testing, only LVEF < 45% and sustained and non-sustained VT remained significant.
In the multivariable model, adjusted for univariable significant risk factors, age at first e event occurred du du du duri r r r n igh int t t ten i i i sit t t ty exerc c c cis is is ise Cumulative event-free survival of individuals with and without these risk factors is shown in Figure 4 . During follow-up, significantly fewer malignant ventricular arrhythmias occurred in individuals without any risk factors (P < 0.001). The current model in this population showed a sensitivity of 90% (95% CI: 80 to 99%), a specificity of 65% (95% CI: 58 to 72%), a positive predictive value of 38% (95% CI: 30 to 46%) and a negative predictive value of 96% (95% CI: 93 to 100%) ( Malignant ventricular arrhythmias occurred in 5 individuals without the presence of the 2 risk factors (LVEF < 45% and sustained or non-sustained VT) at first cardiological evaluation.
Four of them were however identified as high risk patients during clinical follow-up, and received an ICD (detailed information is given in Supplementary table 2) .
Discussion
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(Ta T T T bl b bl ble 4 4 4) ) ) ). The he he d d d di i i iagnos os osti ti ti tic c c c b ab ab bil il i ilit it ity of of of of r r r ris i is isk k k k fact ct t ctor ors s f f fr fro om th th th he e e AC C CC/ C C/ C/AH AH A AHA A/ A (for manage g g ment of f f f pa p p i i tients wit i i h h h h vent i i ri icul l lar arrh h h hyt yt y hm h h h ia i i s and d d d th h h he pr p p evention of i si i
ti i in l l di di l l i isk k i ti ts i i h thi is l lati io f afte b mbi ini in h th follow-up period of more than 1,600 patient-years and demonstrates a significantly increased mortality in this cohort due to the high prevalence of both malignant ventricular arrhythmias and end-stage heart failure.
Mortality and cardiac disease outcome
The family tree mortality ratio method 21, 22 showed a significantly increased SMR in PLN R14del carriers, thereby confirming a poor prognosis as described in multiple small PLN R14del families. 7 In addition, the SMR using the combined end-points (appropriate ICD intervention, cardiopulmonary resuscitation, and heart transplantation) was significantly increased over a broad age range from 20-74 years. This range can be explained by the occurrence of malignant ventricular arrhythmias at a young age and the development of end-stage heart failure at a later age. 10 Accordingly, this corroborates that genetic cascade screening and presymptomatic cardiological screening should be initiated from late adolescence until at least the 8 th decade. In line with previous studies, no cardiac events did occurred before adolescence.
6-8, 10
Malignant ventricular arrhythmias and risk stratification
In addition to a high prevalence of end-stage heart failure and low voltages on ECGs, the phenotype of the PLN R14del mutation carriers is characterized by early onset of ventricular arrhythmias, ranging from a high number of VPC, sustained and non-sustained VT, to malignant ventricular arrhythmias and SCD. It should be noted that these ventricular arrhythmias may be the first clinical presentation and are sometimes fatal. In our cohort 5% presented with malignant ventricular arrhythmias as their first symptom and another 5% presented with sustained VT.
The treatment of asymptomatic cardiomyopathy mutation carriers has been based on their morphological and functional abnormalities, as prescribed by the guidelines or directed by a malignant family history. We have identified two risk factors, namely LVEF < 45% and 
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occurrence of sustained or non-sustained VT, that were significantly associated with malignant ventricular arrhythmias. In the absence of these risk factors, the risk for malignant ventricular arrhythmias is small (< 2%). If we compare these two risk factors with the ones from the ACC/AHA/ESC guidelines (for management of patients with ventricular arrhythmias and the prevention of SCD [criteria are described in Table 4 ]), they were better at identifying PLN R14del mutation carriers at risk for malignant ventricular arrhythmias (sensitivity of 90% vs.
44%), although their specificity was lower (65 vs. 87%). 26 Thus, if we change the cut-off value of LV ejection from < 35% to < 45% and include those with non-sustained VT and not only those with sustained VT, we would miss fewer mutation carriers at risk for malignant ventricular arrhythmias. We concede that these criteria could also lead to some overtreatment. In the absence of these cardiac abnormalities, regular cardiological monitoring remains recommended.
Different environmental and genetic modifiers may contribute to the severity of the cardiac disease. In most forms of cardiomyopathy, avoiding strenuous physical activity is recommended because cardiomyopathies are a major cause of death in young athletes. In addition, some studies on patients with cardiomyopathy describe an association between high dynamic sport activity and the occurrence of malignant ventricular arrhythmias. [27] [28] [29] Excessive mechanical stress, such as long-term high dynamic sport, may accelerate the cardiac disease progression. 13, 29 Interestingly, in our cohort, malignant ventricular arrhythmias (i.e. SCD) occurred more often during exercise, although the exercise intensity varied. However, we found no significant association between the duration of participation in high dynamic sports and malignant ventricular arrhythmias. follow-up and treatment are guided by this classification and differ per type. For DCM, the diagnosis and treatment is mainly guided by functional abnormalities i.e. heart failure, while for ARVC/D the focus is guided more by the ventricular arrhythmias. 31 It is often not possible to discern different cardiomyopathy forms genetically or phenotypically, and overlapping syndromes have been described. 9, 32, 33 In the case of the PLN R14del mutation, the entity of an arrhythmogenic cardiomyopathy subtype, has been suggested. 9, 10, 12 Future more extensive studies are needed to answer the question whether the phenotype caused by PLN R14del mutation is an overlapping entity with ARVC/D or whether it is possible to differentiate on a histological level from ARVC/D as originally described by Marcus et al. 34 At baseline more than one-third of the symptomatic individuals (both index patients and relatives) fulfilled the criteria for DCM and around one-tenth could be diagnosed with ARVC/D, while a minority satisfied the criteria for both diagnoses. In the case of ARVC/D, only in a minority of the patients the full diagnostic work-up was performed (Supplementary table 1) . The number of individuals fulfilling criteria for a specific diagnosis is probably underestimated because diagnostic measurements are believed to be guided by the first presentation and experience of the cardiovascular specialist seen. 9 The overlap between DCM and ARVC/D in PLN R14del mutation carriers means it is challenging to diagnose and treat these patients appropriately and prospective data is essential to help address this problem. Nevertheless, it is important to be aware of the overlap between DCM and ARVC/D in PLN R14del mutation carriers and in a diagnostic workup, measurements for both these cardiomyopathy types needs to be performed. To further elucidate factors contributing to differences in disease phenotype, the study of human induced pluripotent stem cells (hiPSCs) of PLN R14del carriers may be value. Since 1990 the number of genes associated with cardiomyopathies has risen steeply. 2 However, knowledge about genotype-phenotype relations has fallen behind, and is mostly based on limited knowledge obtained from single or several small families. For counselling purposes as well as treating carriers of a putative pathogenic mutation, we need to know more about the natural disease history, particularly since the PLN R14del mutation has also been identified in other European countries, Canada and the USA. [6] [7] [8] [9] Indeed, one of the major problems in clinical practice is the lack of evidence on when best to implant an ICD in carriers of an inherited cardiomyopathy with a high prevalence of malignant ventricular arrhythmias. Current guidelines for ICD implantations do not take genetic background into account and may not be adequate for selecting mutation carriers at risk for malignant ventricular arrhythmias. In line with the results in our PLN R14del cohort, a recent study on lamin A/C mutation carriers observed a high risk for malignant ventricular arrhythmias in patients with LVEF < 45%. 36 Consequently, implementing genotype information into clinical practice could well be pertinent and life-saving.
Overlap between ARVC/D and DCM
Limitations
Our study has some limitations: first, due to its retrospective design, patients were neither diagnosed nor treated based on a standardized protocol. This led to missing data in some individuals, while some potentially interesting prognostic variables, such as the occurrence of fibrosis, could not be included in our analysis. Furthermore, diagnostic data were based on the interpretations of individual physicians as contained in the patients' records. The variables were therefore dichotomized to reduce the effect of different interpretations. The SMR was based on data of proven PLN R14del mutation carriers, including obligate PLN R14del mutation carriers, and based on 23 (5.7%) first-degree relatives who were strongly suspected of carrying the mutation but in whom it was not possible to perform genetic analysis. These individuals were On the other hand the number of malignant ventricular arrhythmias in PLN R14del mutation carriers might be underestimated, because clinical data of prematurely deceased relatives (in whom it was not possible to perform genetic analyses) were not included. Due to the absence of therapy guidelines, the influence of specific therapeutic approaches such as angiotensinconverting enzyme inhibitors or beta blockers could not be analyzed.
In summary, in this large, single-mutation cohort, the cardiac disease outcome in individuals carrying a PLN R14del mutation was characterized by a high prevalence of both malignant ventricular arrhythmias and end-stage heart failure, leading to a high mortality and a 
